Oncobiologics Warrants Series A Exp 18 Feb 2019 (ONSIW) SWOT Analysis / TOWS Matrix / MBA Resources
Strategy / MBA Resources
Introduction to SWOT Analysis
SWOT Analysis / TOWS Matrix for Oncobiologics Warrants Series A Exp 18 Feb 2019 (United States)
Based on various researches at Oak Spring University , Oncobiologics Warrants Series A Exp 18 Feb 2019 is operating in a macro-environment that has been destablized by – wage bills are increasing, technology disruption, customer relationship management is fast transforming because of increasing concerns over data privacy, increasing energy prices, increasing transportation and logistics costs, increasing commodity prices, talent flight as more people leaving formal jobs,
cloud computing is disrupting traditional business models, competitive advantages are harder to sustain because of technology dispersion, etc
Introduction to SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University, we believe that Oncobiologics Warrants Series A Exp 18 Feb 2019 can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Oncobiologics Warrants Series A Exp 18 Feb 2019, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Oncobiologics Warrants Series A Exp 18 Feb 2019 operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 can be done for the following purposes –
1. Strategic planning of Oncobiologics Warrants Series A Exp 18 Feb 2019
2. Improving business portfolio management of Oncobiologics Warrants Series A Exp 18 Feb 2019
3. Assessing feasibility of the new initiative in United States
4. Making a sector specific business decision
5. Set goals for the organization
6. Organizational restructuring of Oncobiologics Warrants Series A Exp 18 Feb 2019
Strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Ability to recruit top talent
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry in United States. It is in a position to attract the best talent available in United States. The firm has a robust talent identification program that helps in identifying the brightest.
Operational resilience
– The operational resilience strategy of Oncobiologics Warrants Series A Exp 18 Feb 2019 comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Learning organization
- Oncobiologics Warrants Series A Exp 18 Feb 2019 is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Oncobiologics Warrants Series A Exp 18 Feb 2019 is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders at Oncobiologics Warrants Series A Exp 18 Feb 2019 emphasize – knowledge, initiative, and innovation.
Digital Transformation in industry
- digital transformation varies from industry to industry. For Oncobiologics Warrants Series A Exp 18 Feb 2019 digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Oncobiologics Warrants Series A Exp 18 Feb 2019 has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Highly skilled collaborators
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive industry. Secondly the value chain collaborators of Oncobiologics Warrants Series A Exp 18 Feb 2019 have helped the firm to develop new products and bring them quickly to the marketplace.
Sustainable margins compare to other players in industry
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has clearly differentiated products in the market place. This has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to fetch slight price premium compare to the competitors in the industry. The sustainable margins have also helped Oncobiologics Warrants Series A Exp 18 Feb 2019 to invest into research and development (R&D) and innovation.
Low bargaining power of suppliers
– Suppliers of Oncobiologics Warrants Series A Exp 18 Feb 2019 in the sector have low bargaining power. Oncobiologics Warrants Series A Exp 18 Feb 2019 has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Oncobiologics Warrants Series A Exp 18 Feb 2019 to manage not only supply disruptions but also source products at highly competitive prices.
Effective Research and Development (R&D)
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in – Oncobiologics Warrants Series A Exp 18 Feb 2019 staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
High switching costs
– The high switching costs that Oncobiologics Warrants Series A Exp 18 Feb 2019 has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Innovation driven organization
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the most innovative firm in sector.
Ability to lead change in
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry in United States. Over the years it has not only transformed the business landscape in the industry in United States but also across the existing markets. The ability to lead change has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Strong track record of project management in the industry
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Compensation and incentives
– The revenue per employee of Oncobiologics Warrants Series A Exp 18 Feb 2019 is just above the industry average. It needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
High dependence on Oncobiologics Warrants Series A Exp 18 Feb 2019 ‘s star products
– The top 2 products and services of Oncobiologics Warrants Series A Exp 18 Feb 2019 still accounts for major business revenue. This dependence on star products in industry has resulted into insufficient focus on developing new products, even though Oncobiologics Warrants Series A Exp 18 Feb 2019 has relatively successful track record of launching new products.
Low market penetration in new markets
– Outside its home market of United States, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
Employees’ less understanding of Oncobiologics Warrants Series A Exp 18 Feb 2019 strategy
– From the outside it seems that the employees of Oncobiologics Warrants Series A Exp 18 Feb 2019 don’t have comprehensive understanding of the firm’s strategy. This is reflected in number of promotional campaigns over the last few years that had mixed messaging and competing priorities. Some of the strategic activities and services promoted in the promotional campaigns were not consistent with the organization’s strategy.
Skills based hiring in industry
– The stress on hiring functional specialists at Oncobiologics Warrants Series A Exp 18 Feb 2019 has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Oncobiologics Warrants Series A Exp 18 Feb 2019 supply chain. Even after few cautionary changes, Oncobiologics Warrants Series A Exp 18 Feb 2019 is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Oncobiologics Warrants Series A Exp 18 Feb 2019 vulnerable to further global disruptions in South East Asia.
High bargaining power of channel partners in industry
– because of the regulatory requirements in United States, Oncobiologics Warrants Series A Exp 18 Feb 2019 is facing high bargaining power of the channel partners. So far it has not able to streamline the operations to reduce the bargaining power of the value chain partners in the industry.
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Oncobiologics Warrants Series A Exp 18 Feb 2019 is slow explore the new channels of communication. These new channels of communication can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
Products dominated business model
– Even though Oncobiologics Warrants Series A Exp 18 Feb 2019 has some of the most successful models in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. Oncobiologics Warrants Series A Exp 18 Feb 2019 should strive to include more intangible value offerings along with its core products and services.
No frontier risks strategy
– From the 10K / annual statement of Oncobiologics Warrants Series A Exp 18 Feb 2019, it seems that company is thinking out the frontier risks that can impact industry. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Ability to respond to the competition
– As the decision making is very deliberative at Oncobiologics Warrants Series A Exp 18 Feb 2019, in the dynamic environment of industry it has struggled to respond to the nimble upstart competition. Oncobiologics Warrants Series A Exp 18 Feb 2019 has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
Oncobiologics Warrants Series A Exp 18 Feb 2019 Opportunities | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Changes in consumer behavior post Covid-19
– consumer behavior has changed in the industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Oncobiologics Warrants Series A Exp 18 Feb 2019 can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Oncobiologics Warrants Series A Exp 18 Feb 2019 can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Better consumer reach
– The expansion of the 5G network will help Oncobiologics Warrants Series A Exp 18 Feb 2019 to increase its market reach. Oncobiologics Warrants Series A Exp 18 Feb 2019 will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Building a culture of innovation
– managers at Oncobiologics Warrants Series A Exp 18 Feb 2019 can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the industry.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in industry, but it has also influenced the consumer preferences. Oncobiologics Warrants Series A Exp 18 Feb 2019 can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Oncobiologics Warrants Series A Exp 18 Feb 2019 can use these opportunities to build new business models that can help the communities that Oncobiologics Warrants Series A Exp 18 Feb 2019 operates in. Secondly it can use opportunities from government spending in sector.
Learning at scale
– Online learning technologies has now opened space for Oncobiologics Warrants Series A Exp 18 Feb 2019 to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Developing new processes and practices
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can develop new processes and procedures in industry using technology such as automation using artificial intelligence, real time transportation and products tracking, 3D modeling for concept development and new products pilot testing etc.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Oncobiologics Warrants Series A Exp 18 Feb 2019 can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Oncobiologics Warrants Series A Exp 18 Feb 2019 can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Using analytics as competitive advantage
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in sector. This continuous investment in analytics has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to build a competitive advantage using analytics. The analytics driven competitive advantage can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Buying journey improvements
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. It can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Creating value in data economy
– The success of analytics program of Oncobiologics Warrants Series A Exp 18 Feb 2019 has opened avenues for new revenue streams for the organization in industry. This can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to build a more holistic ecosystem for Oncobiologics Warrants Series A Exp 18 Feb 2019 products in the industry by providing – data insight services, data privacy related products, data based consulting services, etc.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Threats Oncobiologics Warrants Series A Exp 18 Feb 2019 External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Environmental challenges
– Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Oncobiologics Warrants Series A Exp 18 Feb 2019 can take advantage of this fund but it will also bring new competitors in the industry.
Barriers of entry lowering
– As technology is more democratized, the barriers to entry to industry are lowering. It can presents Oncobiologics Warrants Series A Exp 18 Feb 2019 with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Oncobiologics Warrants Series A Exp 18 Feb 2019.
Shortening product life cycle
– it is one of the major threat that Oncobiologics Warrants Series A Exp 18 Feb 2019 is facing in sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, Oncobiologics Warrants Series A Exp 18 Feb 2019 may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of sector.
Consumer confidence and its impact on Oncobiologics Warrants Series A Exp 18 Feb 2019 demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in industry and other sectors.
Regulatory challenges
– Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the industry regulations.
Stagnating economy with rate increase
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the industry.
Technology acceleration in Forth Industrial Revolution
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has witnessed rapid integration of technology during Covid-19 in the industry. As one of the leading players in the industry, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to keep up with the evolution of technology in the sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Increasing wage structure of Oncobiologics Warrants Series A Exp 18 Feb 2019
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Oncobiologics Warrants Series A Exp 18 Feb 2019.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Oncobiologics Warrants Series A Exp 18 Feb 2019 can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate Oncobiologics Warrants Series A Exp 18 Feb 2019 prominent markets.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to understand the core reasons impacting the industry. This will help it in building a better workplace.
High dependence on third party suppliers
– Oncobiologics Warrants Series A Exp 18 Feb 2019 high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Weighted SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers at Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to make to build a sustainable competitive advantage.